Prelude Therapeutics AI Stock Analysis
Want to see PRLD full AI Analyst Report?
Prelude Therapeutics (PRLD) AI Stock Analysis
Prelude Therapeutics
(NASDAQ:PRLD)
The score is held down primarily by ongoing losses and negative free cash flow, despite improved burn and a relatively stable balance sheet. Technicals also remain bearish with the stock below major moving averages and weak momentum indicators. Offsetting these risks, recent corporate milestones (IND clearance and a Lilly collaboration) provide a positive catalyst backdrop, but not enough to outweigh the current financial and trend weakness.
Prelude Therapeutics (PRLD) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $192.16M
- Dividend Yield
- ―
- Average Volume (3M)
- 474.26K
- Price to Earnings (P/E)
- -5.1
- Beta (1Y)
- 1.33
- Revenue Growth
- 105.44%
- EPS Growth
- 59.69%
- Country
- US
- Employees
- 79
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Prelude Therapeutics Business Overview & Revenue Model
Company Description
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoin...
Prelude Therapeutics Earnings Call Summary
The earnings call highlights strategic advancements and a strong financial partnership with Incyte, positioning Prelude well for future development. However, challenges remain in differentiating their products in competitive spaces and ensuring timely clinical progress.
Q3-2025 Updates
Positive Updates
Negative Updates
Company Guidance
During the Prelude Therapeutics Investor Conference Call, the company provided guidance on its strategic focus and future clinical development activities. Prelude is set to advance two key development candidates into clinical trials by 2026: a JAK2V617F selective inhibitor for myeloproliferative neoplasms (MPN) and a KAT6A selective degrader for ER-positive breast cancer. The JAK2V617F inhibitor targets a mutation present in over 95% of polycythemia vera patients and 50-60% of patients with myelofibrosis and essential thrombocythemia, representing a market of over 200,000 MPN patients in the U.S. alone. The KAT6A program aims to address resistance in ER-positive breast cancer, with preclinical data suggesting a differentiated safety and efficacy profile over existing treatments. Prelude announced a significant $910 million deal with Incyte, including an upfront payment of $60 million, providing a financial runway into 2027, and plans to file an Investigational New Drug (IND) application for the JAK2 program in early 2026.
Prelude Therapeutics Financial Statement Overview
Summary
Financial profile remains weak overall: despite meaningful TTM revenue (~$21.6M) and very strong gross margin (~98%), profitability is deeply negative (TTM net loss ~$53.3M) and free cash flow is still materially negative (~-$28.0M). The balance sheet is a relative strength with modest debt (~$17.6M) and positive equity (~$124.1M), and cash burn has improved versus 2023–2025, but ongoing losses and negative FCF keep financing risk elevated.
Income Statement
34NegativeBalance Sheet
62PositiveCash Flow
39Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 21.57M | 12.14M | 7.00M | 0 | 0 | 0 |
| Gross Profit | 15.53M | 10.43M | 7.00M | 0 | 0 | 0 |
| EBITDA | -53.87M | -97.79M | -125.40M | -120.66M | -114.11M | -110.78M |
| Net Income | -53.31M | -99.50M | -127.17M | -121.83M | -115.44M | -111.69M |
Balance Sheet | ||||||
| Total Assets | 175.49M | 141.31M | 175.51M | 277.67M | 220.50M | 305.10M |
| Cash, Cash Equivalents and Short-Term Investments | 140.00M | 103.21M | 133.61M | 232.94M | 201.73M | 291.23M |
| Total Debt | 17.56M | 17.79M | 18.02M | 16.89M | 1.83M | 1.74M |
| Total Liabilities | 51.35M | 72.68M | 44.06M | 40.58M | 25.06M | 19.20M |
| Stockholders Equity | 124.14M | 68.64M | 131.46M | 237.09M | 195.44M | 285.90M |
Cash Flow | ||||||
| Free Cash Flow | -27.95M | -56.37M | -103.65M | -110.58M | -86.75M | -85.85M |
| Operating Cash Flow | -27.92M | -56.30M | -102.89M | -107.06M | -83.73M | -83.53M |
| Investing Cash Flow | -108.33M | 53.46M | 90.19M | -34.65M | 81.69M | -263.80M |
| Financing Cash Flow | 111.62M | 24.82M | -120.00K | 136.40M | 815.00K | 164.90M |
Prelude Therapeutics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRLD, the sentiment is Negative. The current price of 3.32 is below the 20-day moving average (MA) of 3.72, below the 50-day MA of 3.92, and below the 200-day MA of 4.11, indicating a bearish trend. The MACD of -0.13 indicates Positive momentum. The RSI at 37.48 is Neutral, neither overbought nor oversold. The STOCH value of 14.28 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PRLD.
Prelude Therapeutics Risk Analysis
Prelude Therapeutics disclosed 77 risk factors in its most recent earnings report. Prelude Therapeutics reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksPrelude Therapeutics Peers Comparison
Overall Rating
IMMX51Neutral
PRLD47Neutral
GANX41Neutral
PMVP41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 51Neutral | $603.45M | -8.71 | -24.93% | ― | ― | -5.65% | |
| 47Neutral | $264.95M | -5.08 | -55.14% | ― | 105.44% | 59.69% | |
| 41Neutral | $52.54M | -2.79 | -133.17% | ― | ― | 33.17% | |
| 41Neutral | $92.15M | -0.78 | -110.22% | ― | ― | 3.11% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| PRLD | Prelude Therapeutics, Inc. | 3.32 | 1.65 | 98.80% | |
| PMVP | Pmv Pharmaceuticals, Inc. | 1.22 | -0.14 | -10.29% | |
| GANX | Gain Therapeutics, Inc. | 1.18 | -1.57 | -57.09% | |
| IMMX | Immix Biopharma, Inc. | 7.20 | 2.97 | 70.21% |
Prelude Therapeutics Corporate Events
Prelude Therapeutics Reports Third-Quarter 2026 Financial Results
PositiveOn Nov. 16, 2026, Prelude reported third-quarter 2026 results for the period ended Sept. 30, 2026. Cash, cash equivalents, restricted cash and marketable securities were $142.7 million at quarter-end, while third-quarter R&D expense was $14.8 million...
Prelude Therapeutics IND Cleared for Novel Breast Cancer Drug
PositiveOn September 10, 2026, Prelude Therapeutics announced that the U.S. Food and Drug Administration cleared its Investigational New Drug application for PRT13722, an oral, first-in-class KAT6A selective degrader for HR+/HER2- breast cancer. The company...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 16, 2026
